HCID 57388228, 화합물 → HCID 136378669, 화합물
반응식
[F:1][C:2]1[C:7](=[O:8])[NH:6][C:5]([CH2:9][C:10]([O-:12])=O)=[N:4][C:3]=1[N:13]1[CH2:18][CH2:17][O:16][CH2:15][CH2:14]1.[Na+].[Cl:20][C:21]1[C:29]([F:30])=[CH:28][CH:27]=[C:26]2[C:22]=1[CH2:23][CH:24]([CH3:31])[NH:25]2>>[F:1][C:2]1[C:7](=[O:8])[NH:6][C:5]([CH2:9][C:10]([N:25]2[C:26]3[C:22](=[C:21]([Cl:20])[C:29]([F:30])=[CH:28][CH:27]=3)[CH2:23][CH:24]2[CH3:31])=[O:12])=[N:4][C:3]=1[N:13]1[CH2:18][CH2:17][O:16][CH2:15][CH2:14]1참가 물질
3
실험 절차
The product is prepared by following the procedure described in example 1a (step 5a) using 91 mg of sodium (5-fluoro-4-morpholin-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)acetate and 55 mg of 4-chloro-5-fluoro-2-methyl-2,3-dihydro-1H-indole. After purification, 44 mg of 2-[2-(4-chloro-5-fluoro-2-methyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-3-methyl-6-morpholin-4-yl-3H-pyrimidin-4-one are obtained in the form of a solid, the characteristics of which are the following:
후처리
- customThe product is prepared
- customAfter purification, 44 mg of 2-[2-(4-chloro-5-fluoro-2-methyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-3-methyl-6-morpholin-4-yl-3H-pyrimidin-4-one